

## **FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer**

Stephanie K. Watkins, ... , Hideo Yagita, Arthur A. Hurwitz

*J Clin Invest.* 2015;125(5):2179-2179. <https://doi.org/10.1172/JCI81878>.

### **Retraction**

Original citation: *J Clin Invest.* 2011;121(4):1361–1372. doi:10.1172/JCI44325. Citation for this retraction: *J Clin Invest.* 2015;125(5):2179. doi:10.1172/JCI81878. At the request of the corresponding author, the JCI is retracting the paper “FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer” based on findings of data falsification and fabrication regarding Figures 1D and 8A, likely data falsification regarding Figure 4A, likely falsification or fabrication regarding Figure 4B, and erroneous sample attribution in Table 1. Following extensive review by an NIH-appointed investigation committee, the NIH found that one author, Stephanie Watkins, was the sole individual responsible for the instances of research misconduct. None of the other authors was aware of the misconduct.

**Find the latest version:**

<https://jci.me/81878/pdf>



## Retraction

### FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer

Stephanie K. Watkins, Ziqiang Zhu, Elena Riboldi, Kim A. Shafer-Weaver, Katherine E.R. Stagliano, Martha M. Sklavos, Stefan Ambs, Hideo Yagita, and Arthur A. Hurwitz

Original citation: *J Clin Invest.* 2011;121(4):1361-1372. doi:10.1172/JCI44325.

Citation for this retraction: *J Clin Invest.* 2015;125(5):2179. doi:10.1172/JCI81878.

At the request of the corresponding author, the *JCI* is retracting the paper “FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer” based on findings of data falsification and fabrication regarding Figures 1D and 8A, likely data falsification regarding Figure 4A, likely falsification or fabrication regarding Figure 4B, and erroneous sample attribution in Table 1. Following extensive review by an NIH-appointed investigation committee, the NIH found that one author, Stephanie Watkins, was the sole individual responsible for the instances of research misconduct. None of the other authors was aware of the misconduct.

## Corrigendum

### Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor

Klaus-Dieter Preuss, Michael Pfreundschuh, Martin Weigert, Natalie Fadle, Evi Regitz, and Boris Kubuschok

José Carreras Center for Immuno- and Gene Therapy, Internal Medicine I, Saarland University Medical School, Homburg (Saar), Germany.

Original citation: *J Clin Invest.* 2015;125(1):316-323. doi:10.1172/JCI76802.

Citation for this corrigendum: *J Clin Invest.* 2015;125(5):2179. doi:10.1172/JCI82091.

Martin Weigert was inadvertently omitted from the author list. The correct author and affiliation lists appear above.

The authors regret the error.

## Corrigendum

### CGRP induction in cystic fibrosis airways alters the submucosal gland progenitor cell niche in mice

Weiliang Xie, John T. Fisher, Thomas J. Lynch, Meihui Luo, Turan I.A. Evans, Traci L. Neff, Weihong Zhou, Yulong Zhang, Yi Ou, Nigel W. Bunnett, Andrew F. Russo, Michael J. Goodheart, Kalpaj R. Parekh, Xiaoming Liu, and John F. Engelhardt

Original citation: *J Clin Invest.* 2011;121(8):3144-3158. doi:10.1172/JCI41857.

Citation for this corrigendum: *J Clin Invest.* 2015;125(5):2179. doi:10.1172/JCI82138.

During the preparation of this manuscript, the labels for the data lines in Figure 5, C and D, were inadvertently switched. The correct figure parts are below.

The authors regret the error.

